We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

284 hedge funds and large institutions have $8.36B invested in Medicines Co in 2019 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 71 increasing their positions, 88 reducing their positions, and 66 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more funds holding in top 10

Funds holding in top 10: 1438 (+24)

64% more capital invested

Capital invested by funds: $5.11B → $8.36B (+$3.25B)

62% more first-time investments, than exits

New positions opened: 107 | Existing positions closed: 66

18% more call options, than puts

Call options by funds: $1.12B | Put options by funds: $951M

14% more funds holding

Funds holding: 250284 (+34)

19% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 88

Holders
284
Holders Change
+34
Holders Change %
+13.6%
% of All Funds
5.6%
Holding in Top 10
38
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+171.43%
% of All Funds
0.75%
New
107
Increased
71
Reduced
88
Closed
66
Calls
$1.12B
Puts
$951M
Net Calls
+$173M
Net Calls Change
+$270M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$1.03B +$15M +224,229 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$648M +$10.5M +157,418 +2%
SCM
3
Sarissa Capital Management
Connecticut
$357M
HI
4
HBK Investments
Texas
$330M +$259M +3,880,000 New
FCM
5
Farallon Capital Management
California
$282M +$221M +3,315,000 New
State Street
6
State Street
Massachusetts
$262M -$28.2M -423,176 -12%
CS
7
Credit Suisse
Switzerland
$245M +$188M +2,821,428 +4,440%
Citigroup
8
Citigroup
New York
$216M +$152M +2,275,369 +853%
MC
9
Maverick Capital
Texas
$185M -$114M -1,707,552 -44%
MF
10
Magnetar Financial
Illinois
$161M +$126M +1,892,832 New
AAM
11
Alpine Associates Management
Florida
$135M +$106M +1,590,435 New
AA
12
AQR Arbitrage
Connecticut
$130M +$102M +1,528,417 New
IAM
13
Iridian Asset Management
Connecticut
$123M -$104M -1,552,700 -52%
Westfield Capital Management
14
Westfield Capital Management
Massachusetts
$116M -$340M -5,099,682 -79%
Wells Fargo
15
Wells Fargo
California
$111M +$47M +704,224 +118%
Millennium Management
16
Millennium Management
New York
$110M +$63.5M +951,684 +280%
UBS Group
17
UBS Group
Switzerland
$108M +$50.3M +754,143 +144%
Bank of America
18
Bank of America
North Carolina
$104M +$20.5M +307,362 +34%
DLPIC
19
Davide Leone & Partners Investment Company
United Kingdom
$97.4M +$76.4M +1,146,192 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$92M +$69.4M +1,041,021 +2,493%
Morgan Stanley
21
Morgan Stanley
New York
$89.8M +$50.4M +756,359 +251%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$89.3M +$3.1M +46,525 +5%
Goldman Sachs
23
Goldman Sachs
New York
$83.8M +$23.7M +355,944 +56%
BC
24
Boxer Capital
California
$82.1M +$14.5M +217,000 +29%
UOC
25
UBS O'Connor
Illinois
$82.1M +$64.5M +966,509 New

MDCO Hedge Fund Activity: Q4 2019 in Review

284 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q4 2019, worth a combined $8.36B — up 64% from $5.11B a quarter earlier.

Buyers outnumbered sellers: 107 funds opened new MDCO positions and 66 closed out — a net gain of 41 holders — while 71 added to existing stakes and 88 trimmed.

The largest buyer was HBK Investments, opening a new position worth an estimated $259M. The largest seller was Wellington Management Group, cutting an estimated $709M.

  • 284 institutional investors held Medicines Co (MDCO) as of Q4 2019, up from 250 in Q3 2019.
  • Funds reported $8.36B of Medicines Co stock for Q4 2019, up 64% quarter-over-quarter.
  • 107 funds opened new Medicines Co positions in Q4 2019 and 66 closed out, a net change of +41 holders.
  • The largest Medicines Co buyer in Q4 2019 was HBK Investments, an estimated $259M added.
  • The largest Medicines Co seller in Q4 2019 was Wellington Management Group, an estimated $709M sold.

Based on aggregated 13F filings for Q4 2019.